High-Performance Liquid Chromatographic Determination of SAZ-VII-22, a Novel Antiarrhythmic Agent, in Dog Plasma and Urine

Chen, C. L.; Roder, Joseph D.; Sangiah, S.; Chen, H.; Berlin, K. Darrell; Garrison, G. L.; Scherlag, Benjamin J.; Lazzara, Ralph; Patterson, Eugene

doi:10.2116/analsci.9.429

Cited by 8 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complex I inhibitors include antagonists of the ubiquinone substrate, those which displace the ubisemiquinone intermediate, and antagonists of the ubiquinol product. Specific drugs known to cause this inhibition include amiodarone, propanolol, BRB-I-28, quinidine, and lidocaine [20]. Many pesticides, e.g., rotenone, are complex I inhibitors.…”

Section: Mitochondrial Dysfunctionmentioning

confidence: 99%

Drug-Associated Mitochondrial Toxicity and its Detection

Amacher¹

2005

CMC

View full text Add to dashboard Cite

Mitochondrial dysfunction is a fundamental mechanism in the pathogenesis of several significant toxicities in mammals, especially those associated with the liver, skeletal and cardiac muscle, and the central nervous system. These changes can also occur as part of the natural aging process and have been linked to cellular mechanisms in several human disease states including Parkinson's and Alzheimer's, as well as ischemic perfusion injury and the effects of hyperglycemia in diabetes mellitus. Our knowledge of the effects of xenobiotics on mitochondrial function has expanded to the point that chemical structure and properties can guide the pharmaceutical scientist in anticipating mitochondrial toxicity. Recognition that maintenance of the mitochondrial membrane potential is essential for normal mitochondrial function has resulted in the development of predictive cell-based or isolated mitochondrial assay systems for detecting these effects with new chemical entities. The homeostatic role of some uncoupling proteins, differences in mitochondrial sensitivity to toxicity, and the pivotal role of mitochondrial permeability transition (MPT) as the determinant of apoptotic cell death are factors that underlie the adverse effects of some drugs in mammalian systems. In order to preserve mitochondrial integrity in potential target organs during therapeutic regimens, a basic understanding of mitochondrial function and its monitoring in the drug development program are essential. Toward this end, this review focuses on two topics, (1) the specific effects of xenobiotics on mitochondrial structure and function and (2) a summarization of current methods for quantifying these changes in a preclinical toxicology laboratory.

show abstract

Section: Mitochondrial Dysfunctionmentioning

confidence: 99%

Drug-Associated Mitochondrial Toxicity and its Detection

Amacher¹

2005

CMC

View full text Add to dashboard Cite

show abstract

Pharmacokinetics and Plasma Protein Binding of BRB-I-28, a Novel Antiarrhythmic Agent, in Dogs

et al. 1993

View full text Add to dashboard Cite

SummaryThe pharmacokinetics and plasma protein binding of BRB-I-28, a novel antiarrhythmic agent, were investigated in dogs. The plasma concentration-time profile of BRB-I-28, following an intravenous bolus dose of 10 mgJkg, can be adequately described by a 2-compartment open model. The mean volume of distribution at steady-state (Vdss) was 8.759 L/kg, the mean total systemic clearance (CL) was 1.289 ml/h/kg, and the mean elimination half-life (t' 12/1) was 4.645 hours. Following intravenous administration, approximately 1.85% of the dose was excreted in the urine (0 to 48 hours) as parent drug. Changes in plasma concentrations, after oral administration of BRB-I-28 20 mgJkg, were best described by a l-compartment open model. BRB-I-28 was rapidly absorbed (tmax = 1.22 hours and Cmax = 1.59 mgJL) with a rapid elimination rate (t'12kel = 1.583

show abstract